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Abstract
Background: DNA methylation based techniques are important tools in both clinical diagnostics
and therapeutics. But most of these methods only analyze a few CpG sites in a target region.
Indeed, difference of site-specific methylation may also lead to a change of methylation density in
many cases, and it has been found that the density of methylation is more important than
methylation of single CpG site for gene silencing.
Results: We have developed a novel approach for quantitative analysis of CpG methylation density
on the basis of microarray-based hybridization and incorporation of Cy5-dCTP into the Cy3
labeled target DNA by using Taq DNA Polymerase on microarray. The quantification is achieved
by measuring Cy5/Cy3 signal ratio which is proportional to methylation density. This methylation-
sensitive technique, termed RMEAM (regional methylation elongation assay on microarray),
provides several advantages over existing methods used for methylation analysis. It can determine
an exact methylation density of the given region, and has potential of high throughput. We
demonstrate a use of this method in determining the methylation density of the promoter region
of the tumor-related gene MLH1, TERT and MGMT in colorectal carcinoma patients.
Conclusion: This technique allows for quantitative analysis of regional methylation density, which
is the representative of all allelic methylation patterns in the sample. The results show that this
technique has the characteristics of simplicity, rapidness, specificity and high-throughput.
Background
In the human genome, GC-rich DNA sequences are found
frequently within the promoter and first exon of ~50% of
all genes [1]. These sequences, also known as CpG islands,
can be targets of DNA methylation. An epigenetic phe-
nomenon is known to be associated with genomic
imprinting and X-chromosome inactivation, and essential
for normal mammalian development [2]. Both global
hypomethylation and regional hypermethylation have
been described in human tumor cell lines and a wide
spectrum of cancers [3]. Global hypomethylation has
been associated with instability of chromosomal or mic-
rosatellite, while regional hypermethylation of CpG
islands within promoter region of tumor suppressor genes
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is associated with transcriptional inactivation and repre-
sents an important mechanism of gene silencing in the
pathogenesis of neoplasia [4,5]. There is emerging evi-
dence that each tumor may harbor multiple genes suscep-
tible to promoter hypermethylation. Methylation profiles
of multiple genes for each cancer type might have impor-
tant prognostic implications for clinical monitoring, risk
assessment, and even therapeutic considerations [6-8].
The present techniques commonly used for the methyla-
tion analysis are based on the bisulfite modification of the
genomic DNA. Since sodium bisulfite treatment exclu-
sively converts unmethylated cytosine to uracil under
appropriate conditions [9], subsequent analysis to differ-
entiate unconverted cytosine from converted uracil ena-
bles us to know the primary methylation status. It is the
basis for methylation-specific PCR (MSP) [10], bisulfite
DNA sequencing [11], enzymatic regional methylation
assay (ERMA) [12], pyrosequencing [13], and mass spec-
trometry [14]. MSP is widely used to analyze promoter
methylation, although only a limited number of CpG
sites can be analyzed by this method. Bisulfite DNA
sequencing provides precise methylation status over an
amplified region, but it requires large-scale sequencing of
multiple plasmid clones. The major advantage of the
pyrosequencing method compared to MSP is that the data
are actual sequences rather than fluorescence data from
PCR-based amplification. But highly repetitive thymines
and the limitation of ~75 bp extension length [15] can
affect assay reproducibility and accuracy. Mass spectrom-
etry permits the high-throughput identification of methyl-
ation sites and the semiquantitative measurement at
single or multiple CpG positions, but this method needs
high quality and a large amount of samples, and some-
times false positive results are inevitable. Even though
ERMA can determine overall methylation level within a
region containing a number of CpG sites, but it requires
radioactive labeling of DNA samples and subsequent
cumbersome purification steps of the radiolabeled prod-
ucts. Recently, several groups have shown that the meth-
ylation status can be achieved by 5mC-antibodies or
MBD-proteins [16-18]. However, the affinity and specifi-
city would be further improved for methylation density
detection.
Microarrays provide the powerful tools for mapping the
epigenome and detecting patterns of DNA methylation in
the genome level [19-24]. Methods Coupling CpG-recog-
nizing restriction enzymes with microarray technique
have been reported, such as differential methylation
hybridization (DMH) [19,23], methylation amplification
DNA chip (MAD) [22], and microarray-based integrated
analysis of methylation by isoschizomers (MIAMI) [21].
The above methods are only able to analyze methylation
at the restriction sites of the enzymes, which are poten-
tially biased by mutations or polymorphisms at the sites.
Another microarray approach for methylation pattern
analysis is methylation-specific oligonucleotide (MSO)
microarray [19,20]. MSO uses bisulfite-treated DNA as
template for non-discriminatory PCR amplification, fol-
lowed by hybridization of the PCR products to glass slides
with oligonucleotides that could discriminate between
methylated and unmethylated cytosines at specific CpG
positions. One of the great potentials of MSO is that mul-
tiple genes can be analyzed on the same array. A potential
limitation of this method is that closely spaced CpGs may
not be amenable to analyze if the gene in question is het-
erogeneously methylated. Recently, genomic tiling micro-
array has been used to profile DNA methylation patterns
[24]. But this method can not obtain exact informations
of methylation level within the given region of specific
caner-related genes.
Here, we describe a novel technique for the quantification
of CpG methylation density of a given DNA region, which
combines microarray-based hybridization and enzymatic
elongation on microarray. The quantification is achieved
by measuring Cy5/Cy3 signal ratio which is proportional
to methylation density. In contrast to the other protocols,
this method determines the methylation density of the
entire amplified region, not only of a few CpG sites or
those CpG dinucleotides that are covered by PCR primers/
probes. The results show that this technique allows for the
quantitative analysis of regional methylation density with
simplicity, rapidness, specificity and high-throughput.
Results
Principle of the method
Figure 1 outlines the RMEAM (regional methylation elon-
gation assay on microarray) strategy for DNA methylation
density analysis. Test DNA samples are bisulfite-modified,
PCR amplified products which contain pools of DNA frag-
ments with altered nucleotide sequences due to their dif-
ferential methylation status. As shown, the unmethylated
allele of a given DNA sequence is expected to have the
unmethylated cytosine of the test CpG sites converted to
thymine, whereas these CpG sequences remain
unchanged in the methylated allele. The information on
cytosine methylation can now be converted into sequence
information. The region of interest is amplified with
primers that are specific for bisulfite-modified DNA with-
out CpG dinucleotides in the sequence, which ensures
that the PCR amplification is independent of the original
methylation status. Thus, the number of CpG dinucle-
otides remaining in the amplified region would reflect
original methylation status. Subsequently, the forward
primer was modified with -NH2 at 5' end, and then fixed
on the aldehyde coating glass as probe leaving 3'-OH free.
Target DNA is then hybridized to arrayed oligonucleotide
probes which are specifically designed to match theBMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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reverse strands. For quantification of CpG dinucleotides,
enzymatic elongation was carried out with dNTPs (dATP,
dGTP, dTTP, dCTP, Cy5-dCTP), PCR buffer, Mg2+ and Taq
enzyme on microarray. The incorporation of Cy5-dCTP
into the DNA is proportional to the number of methyl-
ated CpG sites originally present in this DNA region. To
minimize the background signal and solve the problem
that a variable quantity of DNA has different fluorescence
intensities in every reaction tube, we devised a smart way
to accurately standardize between samples. For this step,
we modified Cy3 at the 5'end of reverse primers and the
Cy3 labeled reverse strands were hybridized to the oligo-
nucleotide probes. Because the number of Cy3 is identical
for every PCR product, the Cy3 signal can be used as an
internal control to standardize the amount of DNA that is
finally analyzed. The results are expressed as fluorescence
intensity ratio (Cy5/Cy3). By use of the mixture of fully-
methylated and non-methylated alleles as standards, the
ratios can be converted into percentage values, and thus,
the average methylation density of the amplified region is
determined. However, considering standardization of
Cy3 and Cy5 fluorescence intensity as well as quality con-
trol, we use a positive control (fully-methylated APC allele
from clone) just like the housekeeping gene of cDNA
microarray and a negative control which removes the
influence of cross-hybridization. This positive control has
definite number of CpG sites and merges the PCR prod-
ucts before the hybridization. Thus, the fluorescence
intensity ratios (Cy5sam*Cy3pos)/(Cy5pos*Cy3sam)
will be proportional to the methylation density in the
original sequence (sam: sample; pos: positive control).
Optimization of assay conditions for the MLH1, TERT 
and MGMT promoter region
We determined the feasibility of this RMEAM strategy by
assessing the methylation density of CpG islands located
in the promoter regions of MLH1, TERT and MGMT (Fig.
2A), and it has been proved that the mathylation of
MLH1, TERT and MGMT are associated with carcinogene-
sis of colorectal tumor. A group of forty-arrayed oligonu-
cleotides (Five rows of probes which have eight replicated
spots; See Fig. 2B and Fig. 3A) were designed to hybridize
with the labeled PCR products. The number of CpG sites
in positive control (APC), MLH1, TERT and MGMT were
16, 23, 27 and 28 respectively (Fig. 2A). Fully-methylated
A: Fully-methylated sequences of the 5' untranslated region  of the positive control (fully-methylated APC allele from  clone), MLH1, TERT and MGMT gene are displayed Figure 2
A: Fully-methylated sequences of the 5' untranslated region 
of the positive control (fully-methylated APC allele from 
clone), MLH1, TERT and MGMT gene are displayed. The 
strand shown was amplified using the primers (green color) 
which are specific for bisulfite-modified DNA without CpG 
dinucleotides. B: The nucleotide sequences of probes, the 
length of targets and the number of CpG sites are shown.
Outline for the analysis of gene promoter methylation den- sity Figure 1
Outline for the analysis of gene promoter methylation den-
sity.BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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A: Fully methylated and unmethylated DNA were mixed (0%, 25%, 50%, 75%, 100%) and hybridized to microarray Figure 3
A: Fully methylated and unmethylated DNA were mixed (0%, 25%, 50%, 75%, 100%) and hybridized to microarray. The Cy3 
green and Cy5 red fluorescence signals of MLH1, TERT and MGMT promoter region are shown, reflecting the indicated per-
centage of methylation. From top to bottom, the five probes are positive control (1), negative (2), MLH1 (3), TERT (4) and 
MGMT (5). B: Three calibration curves for measuring methylation densities in MLH1, TERT and MGMT promoter region. The 
intensity ratios (Y-axis) represent signal intensities of (Cy5sam*Cy3pos)/(Cy5pos*Cy3sam).BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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and non-methylated DNA targets amplified from clones
of these three genes were used to test the accuracy and
reproducibility of the RMEAM method. A 182-bp frag-
ment of the MLH1 promoter region, a 224-bp fragment of
the TERT promoter region and a 289-bp fragment of the
MGMT promoter region were amplified by triplex PCR
using primers that were specific for bisulfite-converted
DNAs (Fig. 2B). The fully-methylated alleles generated in
this way had 100% unconverted cytosine in the test CpG
sites, whereas the non-methylated alleles had all cytosine
residues converted into thymine in the amplified DNA.
To evaluate the sensitivity and quantitative accuracy of
our assay as well as determining any possible PCR bias
[25], we then carried out mixing experiments using meth-
ylation positive clones and methylation negative clones.
The mixtures were prepared prior to PCR in order to assess
the possibility of bias during the PCR amplification [12].
The mixtures of Cy3-labeled fully-methylated allele and
non-methylated allele with different proportion merged
the Cy3-labeled positive control. And then a series of
microarray hybridization were performed. After hybridi-
zation, elongation was carried out. Optimal elongation
conditions on microarray were determined in order to
allow elongation reactions to go to completion. Figure 3
shows that there is a linear correlation between the
defined methylation density of the standard clone dilu-
tions and the (Cy5sam*Cy3pos)/(Cy5pos*Cy3sam) sig-
nal ratios. By including mixtures of clones as standards
(fully-methylated only, 75% fully-methylated/25% non-
methylated, 50% fully-methylated/50% non-methylated,
25% fully-methylated/75% non-methylated and non-
methylated only, corresponding to 100%, 75%, 50%,
25% and 0% methylation density) in every assay [12], it is
possible to create a standard curve in order to control for
differential specific activity and incorporation efficiency
of the Cy5-dCTP. This standard curve can then be used to
calculate the methylation density of unknown samples
from the ratios (Cy5sam*Cy3pos)/(Cy5pos*Cy3sam).
All standards and unknown samples were analyzed with
eight replications.
Verification of RMEAM findings by bisulfite sequencing
In order to validate the accuracy of the RMEAM approach,
we analyzed the MLH1, TERT and MGMT promoter meth-
ylation density in 18 colorectal carcinoma patients. Figure
4 showed that this assay could detect precisely the meth-
ylation density in every patient sample. In these samples,
MLH1  promoter had 0%–5.21% methylation density
(mean, 0.78%); TERT  promoter had 1.18%–12.59%
methylation density (mean, 4.48%) and MGMT promoter
had 1.55%–30.84% methylation density (mean 14.44%).
The region of MLH1 promoter in this assay was selected
according to Maekawa et al [26]. This region is a little far-
ther than the region relative to the transcriptional start site
of MLH1 described by Deng et al. [27]. Consequently the
methylation level of this region is relative low.
When we compared our RMEAM results with succedent
bisulfite sequencing data, a high concordance between
both methods was found. Figure 5 showed the correla-
tions between the results obtained by RMEAM with the
data from bisulfite sequencing in MLH1, TERT and
MGMT promoter regions of 18 colorectal tumor patients.
Discussions
We developed a novel approach for quantitative analysis
of CpG methylation density on the basis of microarray-
based hybridization and incorporation of Cy5-dCTP into
the Cy3 labeled target DNAs by using Taq DNA Polymer-
ase on microarray. This method provides several advan-
tages over existing methods for quantitative methylation
analysis. Firstly, it has potential for high-throughput anal-
ysis of DNA methylation profiles. CpG island hypermeth-
ylation has been reported to be linked to the silencing of
many cancer-related genes. A DNA microarray can be
designed and generated to contain a large amount of oli-
gonucleotide probes capturing specifically target genes.
Cancer-related genes can be parallelly amplified from
investigated samples in a 96-well format or with multiple
PCR, which can generate multiple target genes for hybrid-
ization and detection. Secondly, RMEAM can determine
the methylation density of all CpG dinucleotides within
the entire amplified region other than individual CpG
sites. In the case of the MGMT  promoter region, the
detected methylation density includes the methylation
status of 28 CpG dinucleotides. RMEAM produced a lin-
ear response when used for quantitative methylation anal-
ysis in mixing experiments by use of DNA from fully-
methylated and non-methylated clones with a defined
MLH1, TERT and MGMT promoter methylation densities of  tumor samples from 18 patients with colorectal tumor Figure 4
MLH1, TERT and MGMT promoter methylation densities of 
tumor samples from 18 patients with colorectal tumor.BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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methylation status. The third feature of RMEAM is its sim-
plicity and precision. Unlike ERMA method [12], RMEAM
doesn't require radioactive labeling of DNA samples and
subsequent cumbersome purification steps of the radiola-
beled products in tubes. Hybridization, elongation and
washing on microarray can be quickly and easily achieved
within 4 hours. The use of an internal control (Cy3)
allows for correction of potential substrate loss and for
normalization of the results to the DNA amount that is
finally analyzed by microarray scaner. The negative con-
trol in Figure 3 can remove the influence of cross-hybrid-
ization. For example, the net Cy3 intensities of row 1, 3, 4
and 5 of Figure 3A can be derived by subtraction of the
row 2 negative control background. In row 2, the non-spe-
cific hybridization can't bring incorporation of Cy5-dCTP
into the DNA due to the specificity of Taq DNA Polymer-
A: Representative sequencing data of patient No.17 was shown. Red circle indicates the methylated CpG site Figure 5
A: Representative sequencing data of patient No.17 was shown. Red circle indicates the methylated CpG site. 7 clones or less 
per gene in each patient sample were sequenced. B: Correlations between bisulfite sequencing results and methylation density 
data of the MLH1, TERT and MGMT promoter region determined by our new assay in 18 patients with colorectal carcinoma.BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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ase. Dual-color fluorescence can be standardized by posi-
tive control, just like house-keeping gene in cDNA
microarray. The accuracy of our new technique is shown
by the high concordance with bisulfite sequencing data.
However, in this study, only 7 clones or less per gene in
each patient sample were sequenced, which might
account for the slight discrepancies in methylation per-
centages (Figure 5). As cloning and final sequencing of a
small number of alleles does not necessarily give repre-
sentative data for the initial sample, the approach used in
our current assay can provide more informations regard-
ing the overall methylation density of the region from the
sum of all alleles. Furthermore, RMEAM approach is less
costly and labor intensive than the extensive bisulfite
sequencing analysis needed for precise quantitation.
One possible limitation of our method is that it is not
suitable for a detailed characterization of the pattern of
DNA or the determination of methylation status of indi-
vidual CpG sites. However, since difference of site-specific
methylation may also lead to a change of methylation
density in many tumor-related genes, It has been indi-
cated that the methylation density of promoter CpG
islands is more important than methylation occurred at a
specific single CpG site for gene silencing [28-32]. Never-
theless, it has been very difficult to measure the level of
methylation in a target area containing multiple CpG
sites. Results with our new assay might be more biologi-
cally relevant, especially in patient samples with heteroge-
neous methylation patterns. Furthermore, it was
suggested in an in vitro model that de novo CpG island
methylation is not a single event, but rather a progressive
process, and appears to be region specific [33]. Therefore,
it is reasonable to apply a method that accurately deter-
mines the methylation density of a CpG island region in
order to investigate the dynamics of methylation changes
in human malignancies.
One of the potential applications of RMEAM approach is
to examine the changes in methylation patterns following
treatment with demethylating drugs [34]. Galm et al. [12]
had demonstrated the application of ERMA technique for
the quantitative analysis of methylaiton density, in which
KG1a cells were treated in vitro with the increasing 5'aza-
2'-deoxycytidine (DAC) dose within a given time course.
The findings in that paper indicated that the changes of
methylation density could help to optimize the dosage of
demethylating drugs for clinical use by determining the
extent of demethylation at a dose range with little cyto-
toxic side effects. Large-scale screenings of tumor-related
genes under various conditions are needed to elucidate
the functional role of DNA methylation and to screen for
new antineoplastic drugs operative on that mechanism.
Our new method could help elucidate the consequences
of treating patients with such drugs and eventually help
clarify their therapeutic value in future antineoplastic
therapy regimens. Recent evidence has indicated that
increased density of methylation within a susceptible
CpG island is associated with more advanced stages of
tumors. Our RMEAM method coupled with quantitative
real-time PCR approaches to detect gene expression levels
will contribute to more accurately assess the dynamics of
methylation-mediated transcriptional silencing of tumor-
related genes in carcinogenesis. Such assays would prefer-
ably be genome-wide to monitor both desired and unde-
sired effects on methylation and gene expression.
Conclusion
We described a novel approach for quantitative analysis of
CpG methylation density on the basis of microarray-
based hybridization and incorporation of Cy5-dCTP into
the Cy3 labeled target DNA by using Taq DNA Polymerase
on microarray. Our results showed that this RMEAM tech-
nique allows for the quantitative analysis of regional
methylation density with simplicity, rapidness, specificity
and high-throughput.
Methods
Patients and DNA extraction
Informed written consent was obtained from all patients
and donors, and tissue collection was approved by each
Institutional Review Board. The samples of primary tumor
tissues were collected from colorectal carcinoma patients
(n = 18) during surgery at Gulou Hospital and Zhongda
Hospital (Nanjing, China). All tissue samples were fresh-
frozen and stored at -80°C until further processing.
Genomic DNA was extracted from tissues by digesting
with proteinase K (0.5 mg/ml) in 10 mM TE (pH 8.0)
buffer and 0.5% SDS at 48°C overnight, followed by a
standard phenol/chloroform (1:1) extraction and precipi-
tated with ethanol in a standard fashion.
Bisulfite modification of genomic DNA
Bisulfite treatment was carried out following the modified
[35] procedure of Frommer et al. [11]. Briefly, 5 μg of
genomic DNA were digested with EcoRI (New England
Biolabs) and denatured with 0.3 M NaOH for 15 min at
37°C. A freshly prepared solution of sodium bisulfite (2.5
M, pH 5.0) and hydroquinone (100 mM) was added to
the denatured DNA, and the mixture was incubated at
55°C for 5 h. After desalting (Wizard Clean Up System;
Promega), the DNA was desulphonated with 0.3 M NaOH
for 15 min at 37°C. The solution was neutralized with 75
μl of 5 M ammonium acetate (pH 7.0), and the DNA was
ethanol precipitated and resuspended in Tris-EDTA (pH
7.5).
Preparation of the positive and negative clones
Placental DNA treated in vitro with SssI methyltransferase
(New England Biolabs) was used as fully-methylated alle-BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
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les for APC, MLH1, TERT and MGMT gene. Meanwhile,
DNA from normal lymphocytes was used as unmethyl-
ated alleles for MLH1, TERT and MGMT gene. Sodium
bisulfite modification of the unmethylated DNA and M.
SssI-treated DNA were then performed. The targeted CpG
islands (see Fig. 2) were amplified from bisulfite-treated
genomic DNA by triplex PCR using the following primer
pairs [26,36,37]. The primers used were MLH1-Forward,
5'-TTTTTTAGGAGTGAAGGAGG-3';  MLH1-Reverse, 5'-
ATAAAACCCTATACCTAATCTATC-3';  MGMT-Forword,
5'-GGATATGTTGGGATAGTT-3';  MGMT-Reverse, 5'-
CCAAAAACCCCAAACCC-3';TERT-Forward, 5'-GGGT-
TATTTTATAGTTTAGGT-3';  TERT-Reverse, 5'-AATC-
CCCAATCCCTC-3'. These primers are specific for
bisulfite-modified DNA without CpG dinucleotides. The
PCRs were performed in 25-μl reactions containing PCR
buffer with 1.8 mM MgCl2, 5 pmol primer, 1.25 units
Hot-start DNA polymerase (TaKaRa), and 1 μl bisulfite-
modified DNA (equivalent to 50 ng genomic DNA). After
an initial preheating step of 5 min at 95°C, PCR was per-
formed 40 cycles of 95°C for 30 s, 54°C for 30 s, and
72°C for 30 s, with a final extension at 72°C for 7 min.
APC fully-methylated allele was used as positive control
which was amplified by forward primer 5'-GGGGTTAG-
GGTTAGGTAGG-3' and reverse primer 5'-AACTACAC-
CAATACAACCACATA-3' [36]. All PCR products were gel
purified and cloned into the pMD18-T vector according to
the manufacturer's instructions (TaKaRa) and sequenced
using the ABI sequencing system. Quantitation of the PCR
product was performed with a UV spectrometer; 1 OD260
unit was calculated as 50 ng/μL.
Fabrication and hybridization of microarray
Five probes (18–20 nucleotides in length, Fig. 2) were syn-
thesized with an amino-linked C6 [NH2 (CH2)6] linker
attached to its 5'end. Additional 10 nucleotides T were
used to reduce the space influence. Each oligonucleotide
was printed on the aldehyde-coated glass slides using a
PixSys5500 microarrayer (Cartesian Technology Inc).
After printed, the glass slides were incubated in a humid
chamber at room temperature overnight, and then at
37°C for 2 h. The slides were washed thoroughly in 1%
SDS solution to remove unbound oligonucleotides. After
further treatment with a NaBH4 solution for 20 min, the
slides were ready for hybridization. For target DNA labe-
ling, PCR products of bisulfite-treated DNA were labeled
at the 5'end of reverse primer with Cy3. The labeled prod-
ucts were resuspended in hybridization solution (1:3 dilu-
tion v/v). Then the mixture was denatured at 95°C for 5
min, immediately cooled on ice for 10 min and subse-
quently applied to the DNA microarray slides. Microarray
hybridization was conducted in a moist hybridization
chamber under a cover slip at 42°C for 3 h recommended
by Schumacher et al [38].
Elongation on microarray
After hybridization, the slide was rinsed and washed at
room temperature with 2 × SSC-0.1% SDS for 10 min, 0.1
× SSC-0.1% SDS for 5 min, water for 5 min, and then
dried by flowing nitrogen. Then 15 μL elongation system
was applied to the hybridization region with a cover slip.
The elongation system contained 1 × PCR buffer, 2.5 mM
Mg2+, dNTPs (20 μM dGTP, 20 μM dATP, 20 μM dTTP, 0.2
μM dCTP, 0.2 μM Cy5-dCTP), and 1.5 IU Taq DNA
Polymerase (TaKaRa). The incubation procedure was
42°C 10 min, 55°C 5 min, and 72°C 3 min. Subse-
quently, the slide was washed with 2 × SSC-0.5% SDS and
dried, and it was ready to be scanned.
Image scanning and data processing
These microarray slides were scanned with ScanArray Lite
microarray analysis systems (A Packard BioScience Com-
pany, USA). The fluorescence images were analyzed with
GenePix Pro3.0 software. Each spot was defined by the
positioning of a grid of circles over the array image. For
each fluorescent image, the average pixel intensity within
each circle was determined and a local background using
mean pixel intensity was computed for each spot. Net sig-
nal was determined by subtraction of this local back-
ground from the mean average intensity for each spot and
the nospecific influence of cross-hybridization from nega-
tive control. Signal intensities of individual spots were
obtained and exported to Excel spreadsheets for further
analysis. The intensity ratio of Cy5/Cy3 for each probe set
was then obtained.
Authors' contributions
DZ and ZL designed the study and wrote the manuscript,
YW performed the fabrication of microarray and micro-
array hybridization, YB and QG provided the positive and
negative clones of APC, MGMT, MLH1, TERT genes, YQ
performed bisulfite modification and PCR, JL provided
genomic DNA of colorectal cancer tissue samples, and CJ
performed data analysis. All authors read and approved
the final manuscript.
Acknowledgements
This work was funded by the National Natural Science Foundation of China 
(Project 60121101, 60701008), the Hi-Tech Research and Development 
Program of China (Project 2006AA020702), and the National Basic 
Research and Development Program (973 Program) of China (Grant No. 
2006CB705602-9).
References
1. Antequera F, Bird A: Number of CpG islands and genes in
human and mouse.  Proceedings of the National Academy of Sciences
of the United States of America 1993, 90(24):11995-11999.
2. Rountree MR, Bachman KE, Herman JG, Baylin SB: DNA methyla-
tion, chromatin inheritance, and cancer.  Oncogene 2001,
20(24):3156-3165.
3. Jones PA, Takai D: The role of DNA methylation in mamma-
lian epigenetics.  Science 2001, 293(5532):1068-1070.
4. Baylin SB, Herman JG: DNA hypermethylation in tumorigene-
sis: epigenetics joins genetics.  Trends Genet 2000, 16(4):168-174.BMC Genomics 2008, 9:59 http://www.biomedcentral.com/1471-2164/9/59
Page 9 of 9
(page number not for citation purposes)
5. Jones PA, Laird PW: Cancer epigenetics comes of age.  Nature
genetics 1999, 21(2):163-167.
6. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E,
Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Foras-
tiere AA, Baylin SB, Herman JG: Prognostic importance of pro-
moter hypermethylation of multiple genes in esophageal
adenocarcinoma.  Clin Cancer Res 2003, 9(8):2912-2919.
7. Cheng YW, Shawber C, Notterman D, Paty P, Barany F: Multi-
plexed profiling of candidate genes for CpG island methyla-
tion status using a flexible PCR/LDR/Universal Array assay.
Genome research 2006, 16(2):282-289.
8. Muller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A,
Muller-Holzner E, Marth C, Widschwendter M: A DNA methyla-
tion pattern similar to normal tissue is associated with bet-
ter prognosis in human cervical cancer.  Cancer letters 2004,
209(2):231-236.
9. Hayatsu H, Wataya Y, Kai K, Iida S: Reaction of sodium bisulfite
with uracil, cytosine, and their derivatives.  Biochemistry 1970,
9(14):2858-2865.
10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methyla-
tion-specific PCR: a novel PCR assay for methylation status
of CpG islands.  Proceedings of the National Academy of Sciences of the
United States of America 1996, 93(18):9821-9826.
11. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW,
Molloy PL, Paul CL: A genomic sequencing protocol that yields
a positive display of 5-methylcytosine residues in individual
DNA strands.  Proceedings of the National Academy of Sciences of the
United States of America 1992, 89(5):1827-1831.
12. Galm O, Rountree MR, Bachman KE, Jair KW, Baylin SB, Herman JG:
Enzymatic regional methylation assay: a novel method to
quantify regional CpG methylation density.  Genome research
2002, 12(1):153-157.
13. Shames DS, Minna JD, Gazdar AF: Methods for detecting DNA
methylation in tumors: from bench to bedside.  Cancer letters
2007, 251(2):187-198.
14. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos
G, Cantor CR, Field JK, van den Boom D: Quantitative high-
throughput analysis of DNA methylation patterns by base-
specific cleavage and mass spectrometry.  Proceedings of the
National Academy of Sciences of the United States of America 2005,
102(44):15785-15790.
15. Dupont JM, Tost J, Jammes H, Gut IG: De novo quantitative
bisulfite sequencing using the pyrosequencing technology.
Analytical biochemistry 2004, 333(1):119-127.
16. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M:
The affinity of different MBD proteins for a specific methyl-
ated locus depends on their intrinsic binding properties.
Nucleic acids research 2003, 31(6):1765-1774.
17. Jorgensen HF, Adie K, Chaubert P, Bird AP: Engineering a high-
affinity methyl-CpG-binding protein.  Nucleic acids research 2006,
34(13):e96.
18. Roloff TC, Ropers HH, Nuber UA: Comparative study of methyl-
CpG-binding domain proteins.  BMC genomics 2003, 4(1):1.
19. Adorjan P, Distler J, Lipscher E, Model F, Muller J, Pelet C, Braun A,
Florl AR, Gutig D, Grabs G, Howe A, Kursar M, Lesche R, Leu E,
Lewin A, Maier S, Muller V, Otto T, Scholz C, Schulz WA, Seifert HH,
Schwope I, Ziebarth H, Berlin K, Piepenbrock C, Olek A: Tumour
class prediction and discovery by microarray-based DNA
methylation analysis.  Nucleic acids research 2002, 30(5):e21.
20. Gitan RS, Shi H, Chen CM, Yan PS, Huang TH: Methylation-specific
oligonucleotide microarray: a new potential for high-
throughput methylation analysis.  Genome research 2002,
12(1):158-164.
21. Hatada I, Fukasawa M, Kimura M, Morita S, Yamada K, Yoshikawa T,
Yamanaka S, Endo C, Sakurada A, Sato M, Kondo T, Horii A, Ushijima
T, Sasaki H: Genome-wide profiling of promoter methylation
in human.  Oncogene 2006, 25(21):3059-3064.
22. Hatada I, Kato A, Morita S, Obata Y, Nagaoka K, Sakurada A, Sato M,
Horii A, Tsujimoto A, Matsubara K: A microarray-based method
for detecting methylated loci.  Journal of human genetics 2002,
47(8):448-451.
23. Huang TH, Perry MR, Laux DE: Methylation profiling of CpG
islands in human breast cancer cells.  Human molecular genetics
1999, 8(3):459-470.
24. Lippman Z, Gendrel AV, Colot V, Martienssen R: Profiling DNA
methylation patterns using genomic tiling microarrays.
Nature methods 2005, 2(3):219-224.
25. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ:
Detection and measurement of PCR bias in quantitative
methylation analysis of bisulphite-treated DNA.  Nucleic acids
research 1997, 25(21):4422-4426.
26. Maekawa M, Sugano K, Kashiwabara H, Ushiama M, Fujita S, Yoshi-
mori M, Kakizoe T: DNA methylation analysis using bisulfite
treatment and PCR-single-strand conformation polymor-
phism in colorectal cancer showing microsatellite instability.
Biochemical and biophysical research communications 1999,
262(3):671-676.
27. Deng G, Chen A, Hong J, Chae HS, Kim YS: Methylation of CpG in
a small region of the hMLH1 promoter invariably correlates
with the absence of gene expression.  Cancer research 1999,
59(9):2029-2033.
28. Cameron EE, Baylin SB, Herman JG: p15(INK4B) CpG island
methylation in primary acute leukemia is heterogeneous
and suggests density as a critical factor for transcriptional
silencing.  Blood 1999, 94(7):2445-2451.
29. Dodge JE, List AF, Futscher BW: Selective variegated methyla-
tion of the p15 CpG island in acute myeloid leukemia.  Inter-
national journal of cancer 1998, 78(5):561-567.
30. Hsieh CL: Dependence of transcriptional repression on CpG
methylation density.  Molecular and cellular biology 1994,
14(8):5487-5494.
31. Nagasaka T, Sharp GB, Notohara K, Kambara T, Sasamoto H, Isozaki
H, MacPhee DG, Jass JR, Tanaka N, Matsubara N: Hypermethyla-
tion of O-6-methylguanine-DNA methyltransferase pro-
moter may predict nonrecurrence after chemotherapy in
colorectal cancer cases.  Clinical Cancer Research 2003,
9(14):5306-5312.
32. Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC,
Huang TH: Differential distribution of DNA methylation
within the RASSF1A CpG island in breast cancer.  Cancer
research 2003, 63(19):6178-6186.
33. Wong DJ, Foster SA, Galloway DA, Reid BJ: Progressive region-
specific de novo methylation of the p16 CpG island in pri-
mary human mammary epithelial cell strains during escape
from M(0) growth arrest.  Molecular and cellular biology 1999,
19(8):5642-5651.
34. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in
neoplasia: pathophysiology and therapeutic implications.
Annals of internal medicine 2001, 134(7):573-586.
35. Raizis AM, Schmitt F, Jost JP: A bisulfite method of 5-methylcy-
tosine mapping that minimizes template degradation.  Analyt-
ical biochemistry 1995, 226(1):161-166.
36. Clement G, Benhattar J: A methylation sensitive dot blot assay
(MS-DBA) for the quantitative analysis of DNA methylation
in clinical samples.  Journal of clinical pathology 2005, 58(2):155-158.
37. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB,
Herman JG, Belinsky SA: Predicting lung cancer by detecting
aberrant promoter methylation in sputum.  Cancer research
2000, 60(21):5954-5958.
38. Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A,
Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T, Petronis A:
Microarray-based DNA methylation profiling: technology
and applications.  Nucleic acids research 2006, 34(2):528-542.